Short answer: Based on Healthpeak Properties’ second-quarter 2026 results, the company appears able to fund its current dividend from expected adjusted FFO, but the margin is not the same as surplus cash after property investment. Healthpeak’s annualized dividend was $1.22 per share, while management guided to 2026 FFO as Adjusted of $1.73–$1.77 per share. At the $1.75 midpoint, the dividend represents about 70% of adjusted FFO, leaving roughly $0.53 per share before recurring capital spending, debt service and other cash claims.
That is an earnings-coverage conclusion, not a guarantee. FFO as Adjusted is a non-GAAP measure, AFFO and recurring capital expenditures determine how much cash remains, operating trends are mixed, and Healthpeak says future dividends are at the discretion of its board. The latest figures below come from the company’s August 4, 2026 second-quarter release; third-quarter results were not yet available at the October 13 research cut-off.
As an Amazon Associate I earn from qualifying purchases.
The current coverage math
Healthpeak reported $0.46 of diluted FFO as Adjusted per share for the second quarter of 2026 and $0.91 for the first six months. Second-quarter adjusted FFO was unchanged from the same quarter of 2025, while the first-half figure was $0.91 versus $0.92 a year earlier. Management’s updated full-year guidance is $1.73–$1.77 per diluted share, with the August 4 midpoint $0.02 above the May outlook. The figures are in Healthpeak’s second-quarter 2026 earnings release.
The dividend declared for the July-through-September 2026 period was $0.10167 per share each month, or $1.22 annualized. Dividing that annualized amount by each point in the guidance range produces the following implied payout ratios:
#1 Best Overall
| 2026 adjusted FFO assumption | Dividend per share | Implied dividend/FFO payout | FFO above dividend |
|---|---|---|---|
| $1.73 (low end) | $1.22 | 70.5% | $0.51 |
| $1.75 (midpoint) | $1.22 | 69.7% (about 70%) | $0.53 |
| $1.77 (high end) | $1.22 | 68.9% | $0.55 |
These percentages are arithmetic using company-reported figures, not a company-published payout forecast. They indicate that projected adjusted FFO exceeds the declared dividend. They do not show how much cash remains after building improvements, leasing costs, interest, working-capital movements, acquisitions or other uses.
Why FFO coverage is not the same as cash coverage
Real estate investment trusts commonly use funds from operations to explain recurring property earnings. Healthpeak labels its adjusted FFO and net-debt-to-adjusted-EBITDAre figures as supplemental non-GAAP measures and points readers to its reconciliations, definitions and limitations. Adjusted FFO can therefore be a useful earnings yardstick without being equivalent to GAAP net income or cash available for distribution.
For a dividend-funding test, investors normally examine both:
- FFO as Adjusted per share: a measure of recurring operating earnings after the company’s stated adjustments.
- AFFO per share: a cash-oriented measure that typically removes recurring property capital expenditures and other items. The exact definition varies by issuer, so Healthpeak’s reconciliation should be used rather than a generic formula.
Healthpeak’s SEC-filed June 30, 2026 supplement lists AFFO capital expenditures of $42.1 million in the second quarter and $66.1 million for the first six months. Those amounts show why an FFO-only payout ratio can overstate distributable cash, but the cited schedule does not by itself provide a complete AFFO-per-share payout calculation. The supplement is available as a SEC-filed Q2 2026 supplemental report.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
What is driving the earnings outlook?
Healthpeak’s portfolio does not have a uniform operating trend. Second-quarter 2026 same-store adjusted net operating income (NOI) changed as follows:
| Portfolio segment | Q2 2026 same-store adjusted NOI change | What it means for coverage |
|---|---|---|
| Outpatient medical | +2.5% year over year | A positive contribution to recurring property earnings. |
| Laboratory | -3.2% | An offset that requires investigation of occupancy, lease expirations and tenant demand. |
| Senior housing | +19.2% | The strongest reported growth, although concentration and sustainability matter. |
| Total portfolio | +1.8% | Positive overall growth in the quarter, despite the laboratory decline. |
Management raised full-year guidance for total same-store cash adjusted NOI to 0%–1.5%. That range is modest relative to the senior-housing increase and signals that the company expects stronger and weaker assets to balance out. One quarter does not establish a long-term laboratory trend, but the 3.2% decline is the most visible operating pressure in the current coverage case. Third-quarter commentary should clarify whether it reflects temporary items, tenant-specific weakness, leasing downtime or a broader demand issue.
Balance-sheet capacity supports the dividend, but it is a snapshot
As of June 30, 2026, Healthpeak reported net debt equal to 4.7 times adjusted EBITDAre. It reported $3.4 billion of liquidity as of August 3. Both figures suggest access to financial capacity if operating cash flow is temporarily pressured, but they are dated snapshots rather than October balance-sheet measurements. Leverage can rise or fall with asset sales, acquisitions, debt issuance, repayments and changes in EBITDAre.
The company also described several debt actions using proceeds from a Brookfield joint venture and other transactions:
| Action | Amount | Interpretation |
|---|---|---|
| Repayment of 3.25% senior notes at maturity | $650 million | Reduced a scheduled maturity; the proceeds were transaction-related, not recurring rent. |
| Repayment of commercial-paper borrowings | About $375 million | Lowered short-term borrowings after the joint-venture proceeds. |
| Mortgage debt repaid in June 2026 | $142 million | Reduced secured debt during the quarter. |
| Mortgage debt repaid in January 2026 | $103 million | A separate early repayment mentioned in the 2025 Form 10-K. |
Debt repayment can improve refinancing risk and interest expense, but joint-venture proceeds are not a recurring source of dividend cash. The right question is whether properties continue generating enough recurring cash after capital needs while the balance sheet remains within management’s intended range.
What Healthpeak’s dividend policy actually promises
Healthpeak shifted from quarterly to monthly common-dividend payments beginning in April 2025, according to its 2025 Form 10-K. The 2026 declarations reviewed for the July-through-September period were $0.10167 per share per month, equivalent to $1.22 annually. The company’s investor-relations news index lists a fourth-quarter dividend announcement dated October 1, 2026, but the index excerpt does not state the amount; the rate should not be assumed without the underlying release. The index is available at Healthpeak’s investor-relations news page, and the historical filing is the 2025 Form 10-K.
Most importantly, Healthpeak’s earnings release states: “Future dividends are at the discretion of Healthpeak’s Board of Directors.” A declared payment is therefore evidence of the board’s current decision, not a contractual promise that every future monthly dividend will remain unchanged. The board can consider earnings, AFFO, capital requirements, leverage, asset transactions and market conditions when setting future distributions.
What could weaken dividend funding?
Laboratory-property pressure
The laboratory segment’s 3.2% same-store NOI decline is the clearest current operating concern. Lower occupancy, delayed leasing, tenant failures or higher concessions could reduce property cash flow and adjusted FFO. The next report should be checked for occupancy, lease rollover, leasing spreads and management’s explanation before assuming recovery.
Rank #4
Recurring capital spending higher than expected
The $66.1 million of AFFO capital expenditures reported for the first six months is not a forecast for the full year. If building improvements, tenant work or redevelopment spending accelerates, the gap between FFO and cash available for dividends narrows even if adjusted FFO guidance is achieved.
Debt costs and refinancing
A 4.7-times leverage ratio does not eliminate refinancing risk. Interest rates, maturities, fixed-versus-floating debt exposure and access to commercial-paper markets can change the amount of cash left for distributions. Debt repayments are constructive, but they must be evaluated alongside new borrowing and upcoming maturities.
Reliance on asset transactions
Joint-venture proceeds can provide liquidity for maturities or deleveraging. They should not be counted as recurring dividend coverage because they depend on transaction timing, valuation and market demand for properties.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Non-GAAP measurement limits
Adjusted FFO guidance is useful for trend analysis, but its adjustments mean it should be read with the company’s reconciliation. A payout that looks comfortable against FFO can be less comfortable against AFFO after recurring capital expenditures and other cash obligations.
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
How to judge the next quarterly update
When Healthpeak reports third-quarter results, use the same dated period for every calculation. A practical review sequence is:
- Confirm the declared dividend: record the monthly rate and annualize it only after verifying the declaration period.
- Update adjusted FFO: replace the old full-year guidance midpoint with the latest range and calculate dividend per share divided by low, midpoint and high estimates.
- Calculate cash coverage: obtain AFFO per share from the filing and compare it with the annualized dividend. Read the reconciliation to identify recurring capital expenditures and other adjustments.
- Review property operations: compare total and segment same-store cash NOI, occupancy, leasing activity and guidance changes. Pay particular attention to laboratory performance.
- Recheck debt capacity: update net debt-to-adjusted-EBITDAre, liquidity, debt maturities, interest costs and commercial-paper balances.
- Separate recurring and one-time cash: exclude asset-sale, joint-venture and other transaction proceeds from a recurring dividend-coverage estimate.
- Read the dividend language: distinguish a board declaration from any statement about future policy; the board’s discretion remains the governing qualification.
A consistent framework for comparing healthcare REIT coverage
If you compare Healthpeak with another healthcare REIT, apply identical definitions and dates rather than comparing one company’s FFO payout with another company’s AFFO payout. The important axes are:
| Measure | Question to answer |
|---|---|
| FFO and AFFO payout | What percentage of each per-share measure is required for the annual dividend, and how does each issuer define its adjustments? |
| Same-store NOI | Are outpatient medical, laboratory and senior-housing properties growing, flat or declining, and what is the portfolio mix? |
| Balance sheet | What are net debt/EBITDAre, liquidity, maturities and fixed-versus-floating exposure on the same reporting date? |
| Cash uses | How much recurring building investment, development, acquisition, disposition, repurchase and debt repayment competes with the dividend? |
| Dividend policy | Is the figure a board declaration, a stated target or merely an analyst calculation, and when was it published? |
Verdict: earnings coverage looks adequate, cash coverage still needs proof
On the information available from second-quarter 2026, Healthpeak appears capable of funding its $1.22 annualized dividend from 2026 adjusted FFO. The approximately 70% midpoint payout provides a meaningful earnings cushion, while 4.7-times net debt to adjusted EBITDAre and $3.4 billion of reported liquidity add financial flexibility.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →The conclusion should remain qualified. AFFO capital expenditures were $66.1 million through six months, laboratory NOI fell 3.2%, transaction proceeds are not recurring property cash, and the leverage and liquidity figures are dated snapshots. Until third-quarter AFFO, recurring capital spending, operating trends and the latest dividend declaration are available, the strongest defensible statement is that the dividend is covered by projected adjusted FFO—not that it is unconditionally secure from all cash-flow pressures.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
